HDAC8 and hypertensive disorder: In our previous studies, we demonstrated that the selective HDAC8 inhibitor, PCI34051, improved vascular hypertrophy in angiotensin II-induced hypertension (Kee et al., 2019) and the enzymatic activity of HDAC8 was increased in the hearts with deoxycorticosterone acetate-salt induced hypertension (Kee et al., 2013).